Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.

Soong RS, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF.

PLoS One. 2013;8(2):e56912. doi: 10.1371/journal.pone.0056912. Epub 2013 Feb 15.

2.

Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.

Soong RS, Song L, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF.

PLoS One. 2014 Mar 24;9(3):e93162. doi: 10.1371/journal.pone.0093162. eCollection 2014.

3.

Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors.

Sun Y, Peng S, Qiu J, Miao J, Yang B, Jeang J, Hung CF, Wu TC.

Gene Ther. 2015 Jul;22(7):528-35. doi: 10.1038/gt.2015.17. Epub 2015 Mar 19.

4.

Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.

Buchan S, Gr√łnevik E, Mathiesen I, King CA, Stevenson FK, Rice J.

J Immunol. 2005 May 15;174(10):6292-8.

5.

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.

Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, Kang CY.

Cancer Res. 2007 Aug 1;67(15):7477-86.

6.

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.

Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI.

Vaccine. 2009 Sep 4;27(40):5450-9. doi: 10.1016/j.vaccine.2009.07.005. Epub 2009 Jul 19.

7.

Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model.

Yu WY, Chuang TF, Guichard C, El-Garch H, Tierny D, Laio AT, Lin CS, Chiou KH, Tsai CL, Liu CH, Li WC, Fischer L, Chu RM.

Vaccine. 2011 Apr 18;29(18):3489-500. doi: 10.1016/j.vaccine.2011.02.031. Epub 2011 Mar 8.

PMID:
21392590
8.

A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.

Ahn E, Kim H, Han KT, Sin JI.

Cancer Lett. 2015 Jan 28;356(2 Pt B):676-85. doi: 10.1016/j.canlet.2014.10.019. Epub 2014 Oct 22.

PMID:
25449428
9.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
10.

Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.

Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.

Cancer Res. 2003 Nov 15;63(22):7920-5.

11.

A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model.

Liu H, Geng S, Feng C, Xie X, Wu B, Chen X, Zou Q, Wang S, Cui J, Xing R, Li W, Lu Y, Wang B.

Hum Vaccin Immunother. 2013 Oct;9(10):2196-202. doi: 10.4161/hv.25013. Epub 2013 Jun 4.

12.

CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.

Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, Ellenhorn JD.

J Immunol. 2003 Mar 15;170(6):3401-7.

13.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
14.

DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cells.

Miyazaki M, Nakatsura T, Yokomine K, Senju S, Monji M, Hosaka S, Komori H, Yoshitake Y, Motomura Y, Minohara M, Kubo T, Ishihara K, Hatayama T, Ogawa M, Nishimura Y.

Cancer Sci. 2005 Oct;96(10):695-705.

15.

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ.

J Exp Med. 1996 Jan 1;183(1):87-97.

16.

Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models.

Park JS, Sohn HJ, Park GS, Chung YJ, Kim TG.

Cancer Sci. 2011 Aug;102(8):1448-54. doi: 10.1111/j.1349-7006.2011.01974.x. Epub 2011 Jun 23.

17.

Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.

18.

CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination.

Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L, Lin CT, Wu TC.

Gene Ther. 2003 Aug;10(16):1311-20.

PMID:
12883527
19.

Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.

Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N.

Cancer. 2007 Oct 1;110(7):1469-77.

20.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311

Supplemental Content

Support Center